Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...